

**Supplementary Table 3.** Risk factors for death in BCLC A stage patients with HCC (n=570)

Variable	Univariate			Multivariate		
	HR	95% CI	P-value	HR	95% CI	P-value
Etiology						
HBV	Ref					
HCV	1.417	0.830-2.401	0.195	1.248	0.799-1.950	0.330
NBNC	1.778	1.189-2.660	0.005			
Age (years)	1.028	1.011-1.046	0.001	1.028	1.008-1.048	0.005
Male sex	0.950	0.653-1.382	0.788			
Hypertension	1.208	0.869-1.681	0.261			
Diabetes	1.645	1.171-2.311	0.004	1.524	1.060-2.191	0.023
Smoking	0.901	0.653-1.243	0.525			
Alcohol	1.193	0.863-1.648	0.285			
Albumin (g/dL)	0.544	0.417-0.710	<0.001	0.609	0.446-0.833	0.609
Total bilirubin (mg/dL)	1.064	0.842-1.345	0.603			
Prothrombin time (INR)	9.321	3.047-28.516	<0.001	5.622	1.576-20.051	0.008
AST (U/L)	0.998	0.995-1.001	0.246			
ALT (U/L)	0.996	0.992-1.001	0.087			
Tumor size (cm)	0.994	0.949-1.041	0.801			
AFP (ng/ml)	1.000	1.000-1.000	0.800			
PIVKA-II (mAU/ml)	1.000	1.000-1.000	0.005	1.000	1.000-1.000	0.123

BCLC, Barcelona Clinic Liver Cancer; HCC, hepatocellular carcinoma; HBV, hepatitis B virus; HCV, hepatitis C virus; NBNC, non-B non-C; INR, international normalized ratio; AST, aspartate aminotransferase; ALT, alanine aminotransferase; AFP, alpha-fetoprotein; PIVKA-II, prothrombin induced by the absence of vitamin K or antagonist-II; 95% CI, 95% confidence interval; HR, hazard ratio; Ref, reference.